Solid Biosciences (SLDB) Total Non-Current Liabilities (2018 - 2026)

Solid Biosciences has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $18.5 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $18.5 million, down 10.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.5 million (down 10.57% YoY), and the FY2025 annual result was $19.1 million, down 9.93% from the prior year.
• Total Non-Current Liabilities came in at $18.5 million for Q1 2026 at Solid Biosciences, down from $19.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $48.5 million in Q4 2022 to a low of $18.5 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $20.9 million (2024), against an average of $23.7 million.
• Across the five-year window, Total Non-Current Liabilities sank 50.63% in 2023 and decreased 9.93% in 2025, its largest moves.
• Solid Biosciences' Total Non-Current Liabilities stood at $48.5 million in 2022, then tumbled by 50.63% to $23.9 million in 2023, then slipped by 11.62% to $21.2 million in 2024, then declined by 9.93% to $19.1 million in 2025, then dropped by 3.04% to $18.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $18.5 million (Q1 2026), $19.1 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.